Profile data is unavailable for this security.
About the company
Climb Bio, Inc., formerly Eliem Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in Phase I clinical trial.
- Revenue in USD (TTM)0.00
- Net income in USD-64.20m
- Incorporated2018
- Employees9.00
- LocationClimb Bio Inc20 WILLIAM STREET, SUITE 145WELLESLEY HILLS 02481United StatesUSA
- Phone+1 (425) 276-2300
- Fax+1 (302) 636-5454
- Websitehttps://climbbio.com/
More ▼
Mergers & acquisitions
| Acquired company | CLYM:NMQ since announced | Transaction value |
|---|---|---|
| Tenet Medicines Inc | 88.01% | -- |
Data delayed at least 15 minutes, as of Oct 18 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sutro Biopharma Inc | 169.36m | -124.45m | 305.72m | 304.00 | -- | 2.01 | -- | 1.81 | -1.84 | -1.84 | 2.56 | 1.86 | 0.3551 | -- | 19.98 | 560,791.40 | -26.09 | -25.48 | -32.89 | -29.75 | -- | -- | -73.48 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| AC Immune SA | 17.91m | -69.98m | 309.68m | 133.00 | -- | 2.18 | -- | 17.29 | -0.7422 | -0.7422 | 0.1934 | 1.44 | 0.0787 | -- | 28.76 | 134,672.30 | -30.73 | -18.25 | -42.90 | -19.52 | -- | -- | -390.68 | -148.29 | -- | -128.01 | 0.0255 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 313.77m | 14.00 | -- | 2.00 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Design Therapeutics Inc | 0.00 | -50.53m | 316.79m | 57.00 | -- | 1.21 | -- | -- | -0.8982 | -0.8982 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -17.39 | -- | -17.96 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 322.49m | 75.00 | -- | 0.6768 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -64.20m | 336.64m | 9.00 | -- | 1.51 | -- | -- | -2.15 | -2.15 | 0.00 | 3.33 | 0.00 | -- | -- | 0.00 | -37.51 | -- | -38.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.87m | 338.70m | 10.00 | -- | 3.44 | -- | -- | -0.6387 | -0.6387 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -26.89 | -36.79 | -31.76 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1342 | -- | -- | -- | 39.47 | -- | -- | -- |
| Monte Rosa Therapeutics Inc | 5.76m | -130.41m | 338.78m | 103.00 | -- | 1.51 | -- | 58.83 | -2.24 | -2.24 | 0.0967 | 3.66 | 0.0185 | -- | 1.05 | 43,300.75 | -41.88 | -- | -46.47 | -- | -- | -- | -2,264.53 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| XOMA Royalty Corp | 15.24m | -25.10m | 344.11m | 13.00 | -- | 3.43 | -- | 22.58 | -2.22 | -2.22 | 1.17 | 8.58 | 0.0826 | -- | 21.36 | 1,172,231.00 | -9.88 | -4.55 | -10.62 | -4.94 | -- | -- | -119.61 | -31.87 | -- | -- | 0.5471 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| iTeos Therapeutics Inc | 35.00m | -108.14m | 344.40m | 157.00 | -- | 0.5188 | -- | 9.84 | -3.00 | -3.00 | 0.9517 | 18.18 | 0.0481 | -- | 1.52 | 222,929.90 | -14.86 | 5.84 | -15.55 | 7.02 | -- | -- | -308.96 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Inozyme Pharma Inc | 0.00 | -88.56m | 347.55m | 59.00 | -- | 3.64 | -- | -- | -1.46 | -1.46 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -57.76 | -45.00 | -63.48 | -48.90 | -- | -- | -- | -- | -- | -- | 0.3244 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| ProQR Therapeutics NV | 20.33m | -23.41m | 353.68m | 157.00 | -- | 10.22 | -- | 17.40 | -0.2878 | -0.2878 | 0.2498 | 0.4237 | 0.1406 | -- | -- | 129,464.80 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 367.64m | 58.00 | -- | 2.23 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 367.83m | 181.00 | -- | 0.9263 | -- | 29.86 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Nautilus Biotechnology Inc | 0.00 | -69.64m | 369.96m | 164.00 | -- | 1.57 | -- | -- | -0.557 | -0.557 | 0.00 | 1.88 | 0.00 | -- | -- | 0.00 | -23.08 | -- | -23.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Data as of Oct 18 2024. Currency figures normalised to Climb Bio Inc's reporting currency: US Dollar USD
63.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Jun 2024 | 31.42m | 46.85% |
| Deep Track Capital LPas of 02 Jul 2024 | 3.90m | 5.82% |
| Janus Henderson Investors US LLCas of 30 Jun 2024 | 3.25m | 4.85% |
| Affinity Asset Advisors LLCas of 14 Aug 2024 | 1.81m | 2.70% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 696.06k | 1.04% |
| Adage Capital Management LPas of 30 Jun 2024 | 670.36k | 1.00% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 343.71k | 0.51% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 318.58k | 0.48% |
| Sphera Funds Management Ltd.as of 30 Jun 2024 | 215.18k | 0.32% |
| Walleye Capital LLCas of 30 Jun 2024 | 196.39k | 0.29% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
